The Cervical Dysplasia market is expected to grow significantly owing to an increased screening rate and increasing initiatives to create public awareness.
DelveInsight’s Cervical Dysplasia Market Insights report proffers a detailed comprehension of the Cervical Dysplasia Market size by treatment, epidemiology, emerging therapies, Cervical Dysplasia Market share of the individual therapies, current and forecasted Cervical Dysplasia Market size from 2018 to 2030 segmented into 7MM (the USA, EU5 (the UK, Italy, Spain, France, and Germany), and Japan).
Cervical Dysplasia: Overview
Cervical Dysplasia, also known as Cervical Intraepithelial Neoplasia (CIN), is the abnormal growth of cells on the surface of the cervix or endocervical canal – the opening between the uterus and the vagina. It is caused by a common virus called Human Papillomavirus (HPV), a sexually transmitted virus with hundreds of strains. Some of these viruses are low-risk and cause genital warts, and others are high-risk and cause cell changes that can turn into Cervical Dysplasia and cancer.
Some of the common Cervical Dysplasia symptoms are abnormal bleeding that starts and stops between regular menstrual periods or that occurs after sexual intercourse, douching, or a pelvic exam, bleeding after menopause, increased vaginal discharge, and pain during intercourse. There are several Cervical Dysplasia risk factors that relate directly to the risk of HPV. These include having an illness that suppresses the immune system, being on immunosuppressant drugs, and having a sexually active life. Cervical Dysplasia screening includes cytology and HPV testing, alone or in combination. Cervical Dysplasia diagnosis is usually done by a routine Pap smear test.
Cervical Dysplasia Epidemiology Segmentation
The Cervical Dysplasia Market Report proffers epidemiological analysis for the study period 2018-30 in the 7MM segmented into:
- Total Diagnosed Incident Cases of Cervical Dysplasia
- Total Diagnosed Incident Cases for Cervical Dysplasia by Severity
- Total Age group-specific Cases of Cervical Dysplasia
- Total Treated Cases of Cervical Dysplasia
Some of the salient features from the Cervical Dysplasia Market Report:
- The total Cervical Dysplasia Market is expected to rise at a CAGR of 2.1% during the study period 2018-2030.
- Key Cervical Dysplasia companies currently working in the market include names such as Inovio Pharmaceuticals, Brooklyn Immuno Therapeutics, PapiVax, Frantz Viral Therapeutics, and others are developing Cervical Dysplasia treatment therapies.
- The Cervical Dysplasia pipeline therapies include VGX-3100, IRX-2, PVX-2, Artesunate, and others that are expected to launch in the study period.
- The total Cervical Dysplasia market size in the United States is expected to increase with a CAGR of 2.2% in the study period (2018–2030).
- Several complications that are associated with the current Cervical Dysplasia treatment options and high cost will adversely impact the Cervical Dysplasia disease market.
- Among the emerging therapies, Inovio Pharmaceutical’s VGX-3100 and Frantz Viral Therapeutics Artesunate appears to be the drugs that have the potential to transform the Cervical Dysplasia market owing to impressive clinical data.
For further information on Market Impact by Therapies, Download the Cervical Dysplasia Market sample @ Cervical Dysplasia Report Sample
There are different degrees of Dysplasia. Based on the Lower Anogenital Squamous Terminology (LAST) project, pathologists call the specimen Low-grade Squamous Intraepithelial Lesion (LSIL) or High-grade Squamous Intraepithelial Lesion (HSIL). Cervical Dysplasia treatment falls into two general categories: destruction (ablation) of the abnormal area and removal (resection). Both types of treatment are equally effective.
The destruction (ablation) procedures are carbon dioxide laser, electrocautery, and cryotherapy. The removal (resection) procedures are loop electrosurgical excision procedure (LEEP), cold knife conization, and hysterectomy. The Cervical Dysplasia market dynamics are anticipated to change in the coming years owing to the expected launch of emerging therapies such as Inovio Pharmaceuticals’ VGX-3100 which is is an investigational immunotherapy vaccine that includes DNA plasmids targeting the E6 and E7 proteins of human papillomavirus (HPV) types 16 & 18, then another biologic from Frantz Viral Therapeutics namely Artesunate is a semi-synthetic derivative of artemisinin, made by the plant sweet wormwood (Artemisia annua), also Brooklyn Immuno Therapeutics is developing IRX‑2 is a mixed, human-derived cytokine product with multiple active constituents, including Interleukin-2, or IL‑2, and other key cytokines, among many others. The launch of various multiple-stage pipeline products will significantly revolutionize the Cervical Dysplasia market dynamics shortly.
Discover more about which therapy set to grab substantial Cervical Dysplasia Market share @ Cervical Dysplasia Market Share
In the Cervical Dysplasia treatment landscape, there is a need for approved treatments. Therefore, testing new Cervical Dysplasia treatment therapies or looking at different combinations of existing treatments is necessary and will rapidly evolve the Cervical Dysplasia market. In addition to these, the entrance of more key players operating in the Cervical Dysplasia market, the continuously increasing screening rate, and novel treatment approaches are set to be factors responsible for Cervical Dysplasia market growth.
Cervical Dysplasia is a common disorder that is strongly linked to HPV infection. If it goes undetected, Cervical Dysplasia can progress to Cervical Cancer. To prevent this cancer, all the countries in 7MM have a screening in place for the early Cervical Dysplasia diagnosis. As a result of the early detection and treatment, the incidence of cervical cancer is falling. Moreover, the countries have started HPV vaccination to combat HPV-related diseases. Therefore, the incidence of Cervical Dysplasia is expected to fall. The high cost of surgical treatment, and the socio-cultural, as well as the psychological impact of Cervical Dysplasia, lead to a lack of approach to treatment impacting the Cervical Dysplasia market. Several challenges are associated with Cervical Dysplasia diagnosis. The patients are asymptomatic, due to which many of them are unaware of the disease and then often progress to cervical cancer. In addition, the current diagnostic process is extremely complex and costly. All these aspects combined may serve as setbacks for Cervical Dysplasia market growth.
Know which Cervical Dysplasia therapy is expected to score the touchdown first @ Cervical Dysplasia Market Landscape and Forecast
Scope of the Cervical Dysplasia Market Report
- Study Period: 2018-30
- Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
- Key Cervical Dysplasia Companies: Inovio Pharmaceuticals, Brooklyn Immuno Therapeutics, PapiVax, Frantz Viral Therapeutics
- Key Cervical Dysplasia Pipeline Therapies: VGX-3100, IRX-2, PVX-2, Artesunate
- Therapeutic Assessment: Cervical Dysplasia current marketed and emerging therapies
- Market Dynamics: Cervical Dysplasia Market drivers and barriers
- Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter’s five forces, BCG Matrix, Market entry strategies
- Unmet Needs
- KOL’s views
- Analyst’s views
- Market Access and Reimbursement
Table of Contents
|2||Report Introduction of Cervical Dysplasia|
|3||Cervical Dysplasia: Market overview at a glance|
|4||Executive Summary of Cervical Dysplasia|
|5||Organizations contributing toward Cervical Dysplasia|
|6||Disease Background and Overview of Cervical Dysplasia|
|7||Management and Treatment of Cervical Dysplasia|
|8||Cervical Dysplasia Epidemiology and Patient Population|
|9||Cervical Dysplasia Patient Journey|
|10||Cervical Dysplasia Case Reports|
|11||Cervical Dysplasia Marketed Therapies|
|12||Cervical Dysplasia Emerging Therapies|
|13||Cervical Dysplasia: 7 Major Market Analysis|
|14||Cervical Dysplasia Market Outlook|
|15||Unmet Needs in Cervical Dysplasia|
|17||Cervical Dysplasia Market Drivers|
|18||Cervical Dysplasia Market Barriers|
|19||Cervical Dysplasia SWOT Analysis|
Get in touch with our Business executive for Cervical Dysplasia industry analysis @ Cervical Dysplasia Market Landscape Analysis
“Cervical Dysplasia Pipeline Insights, 2022” report by DelveInsight outlays comprehensive insights into the present clinical development scenario and growth prospects across the Cervical Dysplasia market. A detailed picture of the Cervical Dysplasia pipeline landscape is provided, which includes the disease overview and Cervical Dysplasia treatment guidelines, as well as key Cervical Dysplasia companies involved such as Brooklyn Immuno Therapeutics, PapiVax, Frantz Viral Therapeutics, and more.
DelveInsight’s, “Bacterial Vaginosis Pipeline Insight, 2022,” report provides comprehensive insights about 6+ companies and 6+ pipeline drugs in the Bacterial Vaginosis pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products and key Bacterial Vaginosis companies such as Osel Inc, Evofem Biosciences, LUCA Biologics, Melinta Therapeutics, TenNor Therapeutics, Mayfield Pharmaceuticals, Toltec Pharmaceuticals, and many others.
The Global Vaginal Rejuvenation Systems market was valued at USD 5.49 billion in 2020, growing at a CAGR of 10.14% during the forecast period from 2021 to 2026 to reach USD 9.75 billion by 2026. The report covers market trends, market drivers and barriers and key companies involved such as INTERmedic Arfran, Lumenis Be Ltd, VYDENCE® Medical, Candela Medical, Quanta System, MedArt ApS, Sincoheren Ltd, and others.
DelveInsight’s “Cervical Cancer Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Cervical Cancer, historical and forecasted epidemiology, as well as the Cervical Cancer market trends, drivers and barriers as well as key Cervical Cancer companies, involved such as Iovance Biotherapeutics, Advaxis, Agenus, Akeso Biopharma, Altor BioScience, Amgen, Allergan, AstraZeneca, Avastin Biosimilars, GlaxoSmithKline, Novartis, and many others.
DelveInsight’s “Cervical Intraepithelial Neoplasia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of the Cervical Intraepithelial Neoplasia, historical and forecasted epidemiology as well as the Cervical Intraepithelial Neoplasia market trends, drivers and barriers as well as key Cervical Intraepithelial companies involved.
DelveInsight’s, “Cervical Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 70+ companies and 70+ pipeline drugs in the Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, as well as key Cervical Cancer companies involved such as Regeneron Pharmaceuticals, Akesobio, Celgene, AstraZeneca, ImaginAb Inc, Genexine, Merck KGaA, Seagen Inc, and many more.
DelveInsight’s, “Advanced Cervical Cancer Pipeline Insight, 2022,” report provides comprehensive insights about 50+ companies and 50+ pipeline drugs in the Advanced Cervical Cancer pipeline landscape. It covers the pipeline drug profiles, including clinical and non-clinical stage products, as well as key Advanced Cervical Cancer companies involved such as AstraZeneca, GlaxoSmithKline, Human Genome Sciences Inc, Advaxis, Bristol-Myers Squibb, Innovent Biologics, Hookipa Biotech GmbH, Shanghai Henlius Biotech, and many others,
DelveInsight’s “Cervical Dystonia Market Insights, Epidemiology, and Market Forecast-2032” report delivers an in-depth understanding of Cervical Dystonia, historical and forecasted epidemiology as well as the Cervical Dystonia market trends, drivers and barriers as well as key Cervical Dystonia companies involved.
Browse Through Our Blog Posts
- Warm Autoimmune Hemolytic Anemia: A less prevalent disease with prevailing unmet needs
- Iron Deficiency Anemia Market Growth Anticipated to Fuel at a CAGR of 3.7% by 2030
- Warm Autoimmune Hemolytic Anemia Epidemiology forecast segmentation, treatment approaches, and WAIHA market forecast
- Overcoming the prevailing unmet needs in the Beta-Thalassemia Market
Assessing leakage for application of strategic counter by Competitive Intelligence
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.